{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:15:39Z","timestamp":1794021339873,"version":"4.8.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>IDH-wildtype glioblastoma multiforme (GBM), the most lethal primary brain tumor in adults, has a median survival of 12\u201315 months despite maximal multimodal therapy, including resection, radiotherapy, and chemotherapy. However, a rare subset of patients, ranging from 1% to 5%, exhibits a prognosis that defies this expectation, demonstrating prolonged survival beyond two years or late recurrence after a recurrence-free interval exceeding two years. These exceptional outcomes are shaped by tumor biology and the extent of surgical resection, underscoring the pivotal role of neurosurgery in altering GBM's relentless course. This review synthesizes current evidence on the neurosurgical strategies driving such rare successes, illuminated by a striking case of a 67-year-old female who survived 42 months with methylated O6-methylguanine-DNA methyltransferase (MGMT) and telomerase reverse transcriptase (TERT) mutation positivity following gross total resection (GTR) without neuronavigation. Enhanced by intraoperative photographs and serial MRIs, we explore the technical nuances of resection, the impact of vascular complications such as an MCA infarct, and the diagnostic challenges posed by late recurrence, including pseudoprogression. By integrating insights from literature with clinical realities, this work advocates for refined surgical approaches, including optimized resection techniques and intraoperative imaging, to improve outcomes in IDH-wildtype GBM. This approach offers neurosurgeons actionable perspectives to confront this formidable disease.<\/jats:p>","DOI":"10.3389\/fsurg.2026.1717024","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:30:31Z","timestamp":1778477431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Beyond two years: a neurosurgical review of prolonged survival and late recurrence in IDH-wildtype GBM"],"prefix":"10.3389","volume":"13","author":[{"given":"Hasan Ali","family":"Ayd\u0131n","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Zonguldak Bulent Ecevit University","place":["Zonguldak, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"Keskin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Zonguldak Bulent Ecevit University","place":["Zonguldak, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kalayc\u0131","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Zonguldak Bulent Ecevit University","place":["Zonguldak, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.jns10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J Neurosurg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/brain\/awm204","article-title":"Long-term survival with glioblastoma multiforme","volume":"130","author":"Krex","year":"2007","journal-title":"Brain"},{"key":"B7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3171\/2012.12.JNS12125","article-title":"Postoperative ischemic changes following resection of newly diagnosed and recurrent gliomas and their clinical relevance","volume":"118","author":"Gempt","year":"2013","journal-title":"J Neurosurg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3171\/2012.9.JNS1277","article-title":"Multiple resections for patients with glioblastoma: prolonging survival","volume":"118","author":"Chaichana","year":"2013","journal-title":"J Neurosurg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/00006123-199805000-00054","article-title":"Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors","volume":"42","author":"Sawaya","year":"1998","journal-title":"Neurosurgery"},{"key":"B10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1586\/erd.12.42","article-title":"Neuronavigation in the surgical management of brain tumors: current and future trends","volume":"9","author":"Orringer","year":"2012","journal-title":"Expert Rev Med Devices"},{"key":"B12","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3171\/2008.4.17536","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt","year":"2009","journal-title":"J Neurosurg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3171\/2012.9.JNS12504","article-title":"Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article","volume":"117","author":"Bloch","year":"2012","journal-title":"J Neurosurg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nop020","article-title":"MGMT Promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera","year":"2010","journal-title":"Neuro Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-013-1141-6","article-title":"Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss","volume":"126","author":"Arita","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.wneu.2011.06.014","article-title":"The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma","volume":"76","author":"Gulati","year":"2011","journal-title":"World Neurosurg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","article-title":"The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection?","volume":"124","author":"Li","year":"2016","journal-title":"J Neurosurg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(11)70196-6","article-title":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","volume":"12","author":"Senft","year":"2011","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00701-005-0688-y","article-title":"Intra-operative 3D ultrasound in neurosurgery","volume":"148","author":"Unsgaard","year":"2006","journal-title":"Acta Neurochir (Wien)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1001\/jama.2012.12807","article-title":"Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas","volume":"308","author":"Jakola","year":"2012","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1089\/ars.2007.1628","article-title":"Detection and characterization of tumor hypoxia using pO2 histography","volume":"9","author":"Vaupel","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jcp.25896","article-title":"The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials","volume":"233","author":"Binabaj","year":"2018","journal-title":"J Cell Physiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/B978-0-12-802997-8.00005-0","article-title":"Histologic classification of gliomas","volume":"134","author":"Perry","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3174\/ajnr.A2397","article-title":"Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma","volume":"32","author":"Hygino da Cruz","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrneurol.2017.44","article-title":"Advances in neuro-oncology imaging","volume":"13","author":"Langen","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-022-04201-6","article-title":"18F-FET-PET Imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis","volume":"161","author":"Singnurkar","year":"2023","journal-title":"J Neurooncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-015-1432-1","article-title":"Glioblastoma: pathology, molecular mechanisms and markers","volume":"129","author":"Aldape","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/neuonc\/nou005","article-title":"The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone","volume":"16","author":"Molenaar","year":"2014","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1200\/JCO.2011.38.4818","article-title":"Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis","volume":"30","author":"De Witt Hamer","year":"2012","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","article-title":"MRI In patients with high-grade gliomas treated with bevacizumab and chemotherapy","volume":"66","author":"Pope","year":"2006","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/neuonc\/nou158","article-title":"TERT Promoter mutations: a novel independent prognostic factor in primary glioblastomas","volume":"17","author":"Simon","year":"2015","journal-title":"Neuro Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/labinvest.3700070","article-title":"Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma","volume":"84","author":"Brat","year":"2004","journal-title":"Lab Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/neuonc\/not137","article-title":"Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma","volume":"16","author":"Chaichana","year":"2014","journal-title":"Neuro Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11940-014-0284-7","article-title":"Role of surgical resection in low- and high-grade gliomas","volume":"16","author":"Hervey-Jumper","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1470-2045(11)70130-9","article-title":"Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review","volume":"12","author":"Kubben","year":"2011","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.wneu.2014.02.015","article-title":"Is supratotal resection of glioblastoma in noneloquent areas possible?","volume":"82","author":"Duffau","year":"2014","journal-title":"World Neurosurg"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/1097-0142(19940915)74:6%3C1784::aid-cncr2820740622%3E3.0.co;2-d","article-title":"The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas","volume":"74","author":"Berger","year":"1994","journal-title":"Cancer"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1717024\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:30:32Z","timestamp":1778477432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1717024\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":49,"alternative-id":["10.3389\/fsurg.2026.1717024"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2026.1717024","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1717024"}}